Role and Impact of Carbapenem in Nosocomial Infections
Tiphaine M. Goulenok, Kamel Majed and Mehran Monchi
Affiliation: Department of Intensive Care Medicine, Melun General Hospital, 2 rue Freteau de Peny, 77000 Melun, France.
Keywords: Antimicrobial resistance, carbapenem, nosocomial infection, Nosocomial Infections, Gram-negative, antibacterial agents, methicillinresistant Staphylococci, broad-spectrum, penicillin, 5-member thiazolidine ring, cephalosporins, 6-member dihydrothiazine, Streptomyces olivaceus, thienamycin, Ertapenem, panipenem, Lactamases, Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacer, Staphylococcus aureus, CS-023, razupenem, PTZ 601, dehydropeptidase-1, betamipron, imipenem, Acinetobacter baumanii, Gram-positive, Enterococcus faecalis, penicillinbinding protein, Doripenem, ESBLs, AmpC beta-lactamases, Klebsiella pneumoniae, Bacteroides fragilis, OprD porin, quinolones-resistants strains, Acinetobacter baumannii, cystic fibrosis, acute pelvic infections, MRSA, septicaemias
Although carbapenem antibiotics are one of the most effective agents in the treatment of nosocomial infections caused by Gram-negative bacteria, their use is threatened by the emergence of antibiotic resistance. The bacterial resistance to carbapenems parallels their increasing use and has dramatic clinical implications such as increase in mortality and cost of care. This article reviews recently published patents claiming for carbapenem antibacterial agents. New forms including crystalline forms with high oral bioavailability and modified spectrum including methicillinresistant Staphylococci are some of new patents described in this review.
Rights & PermissionsPrintExport